Ngā hua rapu - Cierra N. Sharp
- E whakaatu ana i te 1 - 5 hua o te 5
-
1
Developing better mouse models to study cisplatin-induced kidney injury mā Cierra N. Sharp, Leah J. Siskind
I whakaputaina 2017Revisão -
2
-
3
C57BL/6 mice require a higher dose of cisplatin to induce renal fibrosis and CCL2 correlates with cisplatin-induced kidney injury mā Sophia M. Sears, Cierra N. Sharp, Austin Krueger, Gabrielle B. Oropilla, Douglas Saforo, Mark A. Doll, Judit Megyesi, Levi J. Beverly, Leah J. Siskind
I whakaputaina 2020Artigo -
4
Repeated administration of low-dose cisplatin in mice induces fibrosis mā Cierra N. Sharp, Mark A. Doll, Tess V. Dupre, Parag P. Shah, Subathra Marimuthu, Deanna Siow, Gavin E. Arteel, Judit Megyesi, Levi J. Beverly, Leah J. Siskind
I whakaputaina 2016Artigo -
5
Inhibiting glucosylceramide synthase exacerbates cisplatin-induced acute kidney injury mā Tess V. Dupre, Mark A. Doll, Parag P. Shah, Cierra N. Sharp, Deanna Siow, Judit Megyesi, James A. Shayman, Alicja Bielawska, Jacek Bielawski, Levi J. Beverly, María José Hernandez‐Corbacho, Christopher J. Clarke, Ashley J. Snider, Rick G. Schnellmann, Lina M. Obeid, Yusuf A. Hannun, Leah J. Siskind
I whakaputaina 2017Artigo
Ngā utauta rapu:
Ngā marau whai pānga
Chemotherapy
Cisplatin
Internal medicine
Medicine
Pharmacology
Kidney
Acute kidney injury
Fibrosis
Kidney disease
Dosing
Glomerulosclerosis
Nephrotoxicity
Pathology
Proteinuria
Regimen
Administration (probate law)
Apoptosis
Biochemistry
Biology
Cancer research
Ceramide
Chemistry
Endocrinology
Enzyme
Immunology
Inflammation
Intensive care medicine
Lactosylceramide
Law
Oncology